RAPT Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPT research report →
Range $58 – $58
Price Chart
About the company
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies.
- CEO
- Brian Russell Wong
- IPO
- 2019
- Employees
- 67
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on RAPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.61B
- P/E
- -44.46
- PEG
- -0.67
- P/S
- 0.00
- P/B
- 10.29
- EV/EBITDA
- -45.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -22.27%
- ROIC
- -25.17%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-136,101,000
- Net Income
- $-129,865,000-11.2%
- EPS
- $-3.19-4.6%
- OCF Growth
- +14.2%
- FCF Growth
- +15.0%
- 52W High
- $58.02
- 52W Low
- $5.67
- 50D MA
- $49.05
- 200D MA
- $26.91
- Beta
- 0.44
- RSI (14)
- 79
- Avg Volume
- 2.34M
No earnings-call transcripts are available for RAPT yet.
- Free Float
- 30.2%
- Shares Outstanding
- 27.71M
- Float Shares
- 8.37M
of shares held by institutions
66 13F filers
Buy/sell ratio 0.10. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.19M | ▲ 490.60K |
| Lindbrook Capital, LLC | 27.00K | ▲ 27.00K |
| Two Sigma Advisers, LP | 18.45K | ▲ 18.45K |
| Point72 (Difc) Ltd | 16 | ▲ 16 |
Held by 5 ETFs
Biggest fund positions in RAPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 3, 26 | Lyons-Williams Lori | other | 4,956 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 2,813 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 1,063 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 1,618 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 4,561 |
| Mar 3, 26 | Lyons-Williams Lori | sell | 32,229 |
| Mar 3, 26 | GRAY MARY ANN | other | 4,956 |
| Mar 3, 26 | GRAY MARY ANN | sell | 2,813 |
| Mar 3, 26 | GRAY MARY ANN | sell | 498 |
| Mar 3, 26 | GRAY MARY ANN | sell | 938 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RAPT coverage
Recent articles, reports, and earnings notes.
No research on RAPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAPT report →This Biotech Was Quietly Bought Before a $58 Per Share Takeout
fool.com · Mar 21
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
fool.com · Mar 15
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
fool.com · Feb 25
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
globenewswire.com · Feb 19
Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
defenseworld.net · Feb 12
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
prnewswire.com · Feb 11
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
prnewswire.com · Feb 11
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
prnewswire.com · Feb 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.